Kidney Disease & Nephrology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease

This Phase 2 trial is studying ticagrelor, a pill that may reduce inflammation in adults with chronic kidney disease (CKD). Since inflammation can increase the risk of heart disease, which is a leading cause of death for people with CKD, this study could offer a new way to lower that risk. The trial is recruiting participants in the United States and will last about 12 weeks.

Comparative Feasibility and Effectiveness of Medically Tailored Meals Approaches for Pediatric End-Stage Kidney Disease

This study focuses on children with end-stage kidney disease (ESKD) and compares two types of medically tailored meal programs: cooking education versus home-delivered meals. The goal is to find out which approach is easier to use and more helpful in supporting nutrition. Improving nutrition could enhance the health and quality of life for children managing this serious kidney condition. The study plans to enroll 30 children at Baylor College of Medicine.

UBT251 Injection Phase II Clinical Study (CKD)

This clinical trial in China is testing a new injection called UBT251 in adults who are obese or overweight and have chronic kidney disease. Researchers hope this treatment might improve kidney health and address complications related to weight. The study is currently recruiting and aims to include 180 participants, offering a potential new option for people living with both obesity and CKD.

Impact of Propionic Acid on Regulatory T Cell Function in Children With CKD

This study in Germany is exploring the effects of a dietary supplement called propionic acid on children with advanced chronic kidney disease who are undergoing hemodialysis. The supplement might boost immune function and support intestinal health, which could provide additional support for these children. The trial is recruiting 16 participants and could open new possibilities for managing CKD in pediatric patients.

Blood Biomarkers in Pediatric Kidney Transplant Recipients

This research is testing blood biomarkers to help monitor how well treatments are working for children experiencing rejection of a kidney transplant. Using blood tests instead of invasive biopsies could make it easier and safer to track treatment response. The study is recruiting children with biopsy-proven acute rejection in the United States and may improve care for young transplant recipients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.